Clinical Trials Browser

Phase 1/2 × Withdrawn × nilotinib × Clear all

NCT02973711 2021-02-16

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive